10 Results for "

Deferiprone

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "Deferiprone" in MCE Product Catalog:

49
49 Cited Publications
Cat. No.: HY-B0568
CAS No.: 30652-11-0
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .
loading...
    loading...
Cat. No.: HY-B0568R
CAS No.: 30652-11-0
Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .
loading...
    loading...
Cat. No.: HY-W767164
Research Areas:  

Cardiovascular Disease

Deferiprone O-β-D-glucuronide sodium is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide sodium can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .
loading...
    loading...
Cat. No.: HY-147278
CAS No.: 2646704-10-9
Synonyms: Divesiran; SLN124
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
loading...
    loading...
Cat. No.: HY-160078
CAS No.: 141675-48-1
Research Areas:  

Metabolic Disease

Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .
loading...
    loading...
Cat. No.: HY-B0568S
CAS No.: 1346601-82-8
Deferiprone-d3 is the deuterium labeled Deferiprone (HY-B0568). Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .
loading...
    loading...
Cat. No.: HY-147278A
Synonyms: Divesiran sodium; SLN124 sodium
Manusiran sodium (Divesiran sodium) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran sodium increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran sodium with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran sodium can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
loading...
    loading...
Cat. No.: HY-167814S
Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt is the deuterium labeled Deferiprone O-β-D-glucuronide (HY-160078). Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .
loading...
    loading...
Cat. No.: HY-146669
CAS No.: 2421121-10-8
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

BChE-IN-6 (compound 12) is a potent BChE inhibitor, with a Ki of 0.182 μM. BChE-IN-6 shows chelating capacity on Zn 2+. BChE-IN-6 can be used for Alzheimer’s disease (AD) research .
loading...
    loading...
Cat. No.: HY-183618
Research Areas:  

Cancer

DW-229 is a PROTAC degrader derived from Deferiprone (HY-B0568), targeting Fe(II)/α‑ketoglutarate‑dependent histone lysine demethylases (KDMs). DW-229 degrades KDM2A, KDM3A, KDM5B, KDM4A‑C, KDM5C, KDM6B in breast cancer cells. DW-229 shows IC50 < 0.5 μM against MCF‑7 cells and IC50 of 8.87 μM against MDA‑MB‑231 cells, with high cancer cell selectivity. DW-229 can be used for the research of breast cancer, liver cancer, prostate cancer, lung cancer .
loading...
    loading...